share_log

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Allostery Master Fund LP(7.6%),Allostery Investments LP(7.6%), etc.

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Allostery Master Fund LP(7.6%),Allostery Investments LP(7.6%), etc.

Avalo Therapeutics | SC 13G：超过5%持股股东披露文件-Allostery Master Fund LP(7.6%),Allostery Investments LP(7.6%)等
美股sec公告 ·  05/13 12:44
Moomoo AI 已提取核心信息
On May 1, 2024, a Schedule 13G was filed with the United States Securities and Exchange Commission by Allostery Master Fund LP, Allostery Investments LP, Allostery Investments GP LLC, and individuals Christopher Staral and David Modest, collectively referred to as the Reporting Persons, indicating a collective ownership of 78,255 shares of Avalo Therapeutics, Inc. This represents approximately 7.6% of the company's outstanding common stock. The filing, made under Rule 13d-1(c), indicates that the shares are beneficially owned and that the Reporting Persons have shared voting and dispositive power over these shares. The principal business address for all Reporting Persons is in Stamford, CT. Avalo Therapeutics, Inc., the issuer, is based in Rockville, MD. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
On May 1, 2024, a Schedule 13G was filed with the United States Securities and Exchange Commission by Allostery Master Fund LP, Allostery Investments LP, Allostery Investments GP LLC, and individuals Christopher Staral and David Modest, collectively referred to as the Reporting Persons, indicating a collective ownership of 78,255 shares of Avalo Therapeutics, Inc. This represents approximately 7.6% of the company's outstanding common stock. The filing, made under Rule 13d-1(c), indicates that the shares are beneficially owned and that the Reporting Persons have shared voting and dispositive power over these shares. The principal business address for all Reporting Persons is in Stamford, CT. Avalo Therapeutics, Inc., the issuer, is based in Rockville, MD. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
2024年5月1日，Allostery Master Fund LP、Allostery Investments LP、Allostery Investments GP LLC以及个人克里斯托弗·斯塔尔和大卫·莫德斯特（统称为 “申报人”）向美国证券交易委员会提交了附表13G，表示集体拥有Avalo Therapeutics, Inc.78,255股股票。这约占该公司已发行普通股的7.6％。根据第13d-1（c）条提交的文件表明，这些股份是实益所有的，申报人对这些股票拥有共同的投票权和处置权。所有申报人的主要营业地址均在康涅狄格州斯坦福德。发行人Avalo Therapeutics, Inc. 总部位于马里兰州罗克维尔。该文件称，收购这些股票不是为了改变或影响发行人的控制权。
2024年5月1日，Allostery Master Fund LP、Allostery Investments LP、Allostery Investments GP LLC以及个人克里斯托弗·斯塔尔和大卫·莫德斯特（统称为 “申报人”）向美国证券交易委员会提交了附表13G，表示集体拥有Avalo Therapeutics, Inc.78,255股股票。这约占该公司已发行普通股的7.6％。根据第13d-1（c）条提交的文件表明，这些股份是实益所有的，申报人对这些股票拥有共同的投票权和处置权。所有申报人的主要营业地址均在康涅狄格州斯坦福德。发行人Avalo Therapeutics, Inc. 总部位于马里兰州罗克维尔。该文件称，收购这些股票不是为了改变或影响发行人的控制权。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息